Novavax tumbles after Politico report on COVID-19 vaccine production delay

Published by

(Reuters) – Shares of Novavax Inc fell 20% after a report from Politico said the company faces significant hurdles in proving it can manufacture its experimental COVID-19 vaccine that meets regulators’ quality standards, resulting in production delays. The methods Novavax used to test the purity of its vaccine have fallen short of U.S. regulators’ standards, according to the Politico report, citing people familiar with the matter. Novavax in a statement said it was confident in its ability to deliver its high-quality vaccine. “We underscore our ongoing commitment to the stringent standards of …

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *